28
Jun

2017

Support for the Amyloid Theory and Potential Preventative Treatment

The GliaCure team was excited by a recent study out of the University of Finland. Led by Mikko Hiltunen, the group provided support for the hypothesis that amyloid beta (Aβ) plays a key role in the pathology of Alzheimer’s disease. Five years ago an Icelandic team discovered that a mutation in the amyloid precursor protein…more »

04
May

2017

Haydon Lab Discovers Role of Astrocytes in Schizophrenia

On May 4, 2017 GliaCure President Philip Haydon’s laboratory at Tufts University published its findings on the role of astrocytes in schizophrenia in the journal Neuron. N-methyl D-aspartate receptors (NMDARs) play a direct role in many aspects of brain physiology. It is hypothesized that diminished functioning of synaptic NMDAR signaling underlies the etiology of schizophrenia.…more »

30
Jan

2017

GliaCure Highlighted in ADDF Top 5 Advances Report

The Alzheimer’s Drug Discovery Foundation (ADDF) recently reported on the top five Alzheimer’s research advances of 2016. Among these advances was the increasing evidence supporting a key role for neuroinflammation in the progress of Alzheimer’s disease. The article specifically referenced GliaCure’s Phase 1 trial in mild to moderate Alzheimer’s patients using GC021109, which targets inflammation.…more »

26
Apr

2016

Phil Haydon’s Alzheimer’s Research Featured in Tufts Now

GliaCure President Phil Haydon’s research on Alzheimer’s disease is featured in Tufts Now, the online content and information hub for the university community. The article, authored by Bruce Morgan, details the initial resistance by the scientific community to the hypothesis that glia play an active role in brain signaling, Phil’s first discoveries regarding the role…more »

16
Dec

2015

GliaCure Completes Successful Proof of Concept Phase 1b Clinical Trial in Alzheimer’s Disease

GliaCure, a privately-held biotechnology company focused on the development of novel therapies for neurological and neuropsychiatric disorders based on glial targets, announced yesterday that it has successfully completed a Phase 1b clinical trial of its lead product candidate, GC021109, a compound developed as a disease-modifying treatment for Alzheimer’s disease. The trial, which began in February 2015,…more »

20
Oct

2015

GliaCure President presents at ADDF, Society for Neuroscience conferences

On October 6 GliaCure President Phil Haydon presented an invited talk at the ADDF’s 16th International Conference on Alzheimer’s Drug Discovery in New Jersey. In his presentation, titled, “The P2Y6 receptor as a therapeutic target for Alzheimer’s disease”, Phil outlined the strategy underlying the company’s approach to development of a therapy to halt disease progression…more »

12
May

2015

GliaCure Initiates Phase 1b Dosing in Alzheimer’s Patients

GliaCure, a privately-held biotechnology company focused on the development of novel therapies for neurological and neuropsychiatric disorders based on glial targets, announced that it has initiated dosing of Alzheimer’s patients in a Phase 1b clinical trial of its lead product candidate, GC021109, a compound developed as a potential disease-modifying treatment. GliaCure’s innovative approach to treating…more »

17
Mar

2015

GliaCure Receives $1 Million Grant for Phase 1b Alzheimer’s Clinical Trial

Glia-based approach to Alzheimer’s disease provides a novel opportunity for treatment GliaCure, a biotechnology company developing innovative therapies based on glial targets, announced today that it has been awarded a $1 million grant by the Alzheimer’s Drug Discovery Foundation (ADDF) to co-fund a Phase 1b clinical trial in patients with mild to moderate Alzheimer’s disease.…more »

18
Dec

2014

Independent support for the role of microglia in Alzheimer’s disease

I was very excited to read about research recently published by a group from Stanford regarding the potential role for microglia in Alzheimer’s disease (http://med.stanford.edu/news/all-news/2014/12/blocking-receptor-in-brains-immune-cells-counters-alzheimers.html). While the work by Karin Andreasson and her team focuses on a receptor protein called EP2, the underlying conclusions of her research – that restoring the activity of microglia to…more »

18
Nov

2014

GliaCure’s Lead Product, GC021109, Receives FDA Fast Track Designation

GliaCure’s lead product candidate for Alzheimer’s disease, GC021109, has been awarded Fast Track status by the FDA. Biological products are eligible for Fast Track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. The Fast Track…more »

Page 1 of 5